GlassScriptPhysician profile
Madison Martin
NPI 1770206385
$4,391.49
in general payments reported to CMS, 2019-2025
27 companies · $1,882 in 2025
The $1,882 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $977 · 2024: $1,532 · 2025: $1,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,391.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,010.47 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $695.32 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $538.47 | 2023-2025 | |
| Lilly USA, LLC | $353.48 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $324.65 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $168.89 | 2024-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.75 | 2024-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.17 | 2024-2025 | Jardiance |
| Axsome Therapeutics, INC. | $111.07 | 2024-2025 | Auvelity, Symbravo |
| Otsuka America Pharmaceutical, INC. | $107.47 | 2023-2025 | Rexulti |
| Pfizer INC. | $105.46 | 2023-2025 | |
| Biogen, INC. | $102.39 | 2024-2025 | Skyclarys |
| Lundbeck LLC | $102.08 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $95.77 | 2023-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $89.68 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $80.58 | 2023 | Verquvo, Belsomra, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $30.29 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $30.09 | 2024 | Quviviq |
| Seqirus USA INC | $29.26 | 2025 | Fluad, Flucelvax |
| Novartis Pharmaceuticals Corporation | $28.42 | 2023-2024 | |
| Corcept Therapeutics | $23.41 | 2025 | Korlym |
| Astellas Pharma US INC | $22.09 | 2024 | Veozah |
| Amgen INC. | $20.00 | 2025 | Otezla, Repatha |
| Exact Sciences Corporation | $17.19 | 2023 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $14.97 | 2023 | |
| Ardelyx, INC. | $14.81 | 2025 | Ibsrela |
| Sanofi-Aventis U.S. LLC | $14.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.